Published in Blood on December 02, 2004
A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood (2007) 2.19
Discovery of Time-Delayed Gene Regulatory Networks based on temporal gene expression profiling. BMC Bioinformatics (2006) 1.18
KIAA0101 is overexpressed, and promotes growth and invasion in adrenal cancer. PLoS One (2011) 0.91
Small compound 6-O-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myeloma. PLoS One (2011) 0.91
Generation and characterization of the Anp32e-deficient mouse. PLoS One (2010) 0.89
Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance. PLoS One (2011) 0.89
Cracking the ANP32 whips: important functions, unequal requirement, and hints at disease implications. Bioessays (2014) 0.88
Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis. BMC Cancer (2005) 0.87
Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan. Mod Pathol (2015) 0.86
Expression of Hsp90α and cyclin B1 were related to prognosis of esophageal squamous cell carcinoma and keratin pearl formation. Int J Clin Exp Pathol (2014) 0.86
Cyclin b1 suppresses colorectal cancer invasion and metastasis by regulating e-cadherin. PLoS One (2015) 0.79
Software-automated counting of Ki-67 proliferation index correlates with pathologic grade and disease progression of follicular lymphomas. Am J Clin Pathol (2013) 0.76
ANP32B deficiency impairs proliferation and suppresses tumor progression by regulating AKT phosphorylation. Cell Death Dis (2016) 0.75
Differentially correlated genes in co-expression networks control phenotype transitions. F1000Res (2016) 0.75
Birt-Hogg-Dubé syndrome: diagnosis and management. Lancet Oncol (2009) 3.60
Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol (2007) 3.32
Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol (2008) 3.21
Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst (2005) 3.19
Solid cancers after allogeneic hematopoietic cell transplantation. Blood (2008) 2.56
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood (2011) 2.54
Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA (2007) 2.51
Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol (2011) 2.34
Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood (2007) 2.32
Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst (2006) 2.23
Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer (2007) 2.16
CD146 expression on primary nonhematopoietic bone marrow stem cells is correlated with in situ localization. Blood (2011) 2.16
Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood (2010) 2.12
Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol (2011) 2.11
Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell (2013) 2.06
ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome. Nat Methods (2007) 2.04
Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis. Br J Haematol (2007) 2.02
Free light chains and the risk of AIDS-defining opportunistic infections in HIV-infected individuals. Clin Infect Dis (2012) 2.01
Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer (2009) 2.01
Gene family clustering identifies functionally associated subsets of human in vivo blood and tonsillar dendritic cells. J Immunol (2005) 1.93
Activation of telomerase by human cytomegalovirus. J Natl Cancer Inst (2009) 1.92
Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable. Blood (2002) 1.90
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood (2010) 1.89
Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol (2009) 1.88
Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest (2011) 1.87
Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology (2009) 1.80
Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood (2008) 1.78
Minimal residual disease: what are the minimum requirements? J Clin Oncol (2014) 1.76
Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood (2007) 1.73
Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood (2013) 1.64
Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica (2006) 1.64
The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy. Haematologica (2006) 1.63
Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood (2008) 1.61
The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica (2006) 1.59
Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev (2008) 1.59
Hoxb4-deficient mice undergo normal hematopoietic development but exhibit a mild proliferation defect in hematopoietic stem cells. Blood (2004) 1.58
Cryptic subtelomeric 6p deletion in a girl with congenital malformations and severe language impairment. Eur J Hum Genet (2003) 1.56
Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry. Leuk Lymphoma (2011) 1.56
Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol (2007) 1.54
Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase. Leuk Lymphoma (2006) 1.52
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol (2014) 1.52
Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol (2011) 1.51
Reduced proliferative capacity of hematopoietic stem cells deficient in Hoxb3 and Hoxb4. Mol Cell Biol (2003) 1.50
Concomitant and antecedent deep venous thrombosis and cancer survival in male US veterans. Leuk Lymphoma (2011) 1.50
Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia. Haematologica (2009) 1.50
Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthritis Rheum (2008) 1.50
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol (2012) 1.48
Bi-orientation of achiasmatic chromosomes in meiosis I oocytes contributes to aneuploidy in mice. Nat Genet (2007) 1.47
Immunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr (2010) 1.47
Second malignancies after multiple myeloma: from 1960s to 2010s. Blood (2012) 1.46
Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol (2012) 1.46
Profiling of copy number variations (CNVs) in healthy individuals from three ethnic groups using a human genome 32 K BAC-clone-based array. Hum Mutat (2008) 1.45
Familial aggregation and heterogeneity of non-Hodgkin lymphoma in population-based samples. Cancer Epidemiol Biomarkers Prev (2005) 1.45
Proteomic analysis and discovery using affinity proteomics and mass spectrometry. Mol Cell Proteomics (2011) 1.44
Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma. Leuk Lymphoma (2012) 1.43
Predicting the risk of multiple endocrine neoplasia type 1 for patients with commonly occurring endocrine tumors. Eur J Endocrinol (2012) 1.43
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib. Leuk Lymphoma (2014) 1.43
CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res (2008) 1.42
CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma (2010) 1.41
Does granulocyte colony-stimulating factor improve long-term outcome in adult acute lymphoblastic leukemia? Leuk Lymphoma (2009) 1.41
Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Mod Pathol (2009) 1.39
Borrelia and subsequent risk of solid tumors and hematologic malignancies in Sweden. Int J Cancer (2012) 1.39
Cancer risk among patients with myotonic muscular dystrophy. JAMA (2011) 1.38
Serum free light chains as predictors of lymphomagenesis in patients with autosomal dominant hyper-immunoglobulin E syndrome (Job's syndrome). Leuk Lymphoma (2012) 1.38
[QF-PCR or karyotyping in amniocentesis most often not the woman's decision. Difficult to give basis for an informed choice]. Lakartidningen (2007) 1.38
Detection of pancreatic cancer using antibody microarray-based serum protein profiling. Proteomics (2008) 1.38
TGF-beta signaling-deficient hematopoietic stem cells have normal self-renewal and regenerative ability in vivo despite increased proliferative capacity in vitro. Blood (2003) 1.37
Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association. Gastroenterology (2008) 1.36
Inactivation of BHD in sporadic renal tumors. Cancer Res (2003) 1.36
Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma. Haematologica (2009) 1.34
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol (2003) 1.33
Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol (2005) 1.31
Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood (2005) 1.30
Autoimmunity and lymphomagenesis. Int J Cancer (2009) 1.29